Genotyping of Human Immunideficiency Virus type-1 in realation to Antiretroviral drug resistance in Western Province, Kenya

Thumbnail Image
Adungo, Fedinard Onyakasit
Journal Title
Journal ISSN
Volume Title
Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS) is the main pandemic in the world today. Sub-Saharan Africa bears the brunt of the catastrophe. Although it harbours less than 10% of the world's population, it comprises 60% of all people living with HIV/AIDS globally. Kenya has a National adult HIV/AIDS prevalence of 7.4%. In recent times, expansion of access to antiretroviral therapy in resource-limited settings has gained prominence. However, it is estimated that in Africa, only one million people out of the over four million are receiving ART. Highly active antiretroviral therapy has markedly improved the prognosis of HIV -infected patients by controlling HIV replication. However, it has been observed that HAART fails to control HIV replication in an increasing number of patients as a result of a complex array of causes. One of these is the emergence of drug resistance leading to antiretroviral therapy failure. More seriously, HIV drug resistance can be transmitted and lead to treatment failure. The main objective of this study was to determine the circulating HIV -1 SUbtypes in Western Kenya, and the prevalence of mutations in the protease gene that confer antiretroviral resistance in the various SUbtypes. A total of 7S patients were sampled randomly from a cohort of 1000 clients receiving ARVs in Busia District Hospital. A single blood draw (Sml) was collected. packaged and shipped to KEMRI HIV laboratories in Nairobi for genotyping and analysis of drug associated mutations. Polymerase chain reaction. sequencing and phylogenetic analysis of HIV -1 partial protease showed that majority of strains were of SUbtype Al (39/7S) followed by D (21/7S), C (S/7S) and G (S/7S) with possible recombinants of AC (1/7S) and AD (1/7S). Other prevalent SUbtypes included, A2 (2/7S) and B(I/7S). The generated sequences were further analysed using the sequence analysis Stanford HIV drug resistance database for drug-associated resistance mutations. Resistance associated mutations were detected in 12 (16.0%) isolates as follows: Subtypes A I (n= 10), SUbtype G (n= I) and subtype C (n=I). The analysis further indicated that major protease mutations such as D30N. V32I, M46I, and I47L were circulating in this region among patients unexposed to this class of ARVs. This is contrary to the earlier observations in which these mutations have been documented mainly in patients on protease-based regimens, an aspect attributed to transmitted-resistance mutations. A total of 4 SUbtypes A I isolates were found to posses V32L and T74S mutations that result to reduced susceptibility to Nelfinavir. One SUbtype C isolate had D30N. G48R and G73S mutations, which are known to cause high-level resistance to Nelfinavir. Other minor protease mutations such as M36I and K201 were also detected. Such mutations are common to some patients not previously exposed to ARVs, especially in non-B SUbtypes. There is need for regular surveillance of drug resistance and monitoring of mutations conferring resistance to' ARVs in both treated and untreated patient population in order to achieve 'Successful treatment outcomes.
Department of Zoological Sciences,81p.The RA 644 .A25A38 2011
Aids(Disease) --Kenya --Western province | HIV infections --Kenya --Western province